Announced
Completed
Synopsis
Boehringer Ingelheim Venture Fund, a corporate venture capital firm, led a funding round in ArrePath, a biotechnology company, with participation from Insight Partners, Innospark, Nor’easter Ventures, and AB Magnitude. Financial terms were not disclosed. “We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath. This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria,” Kevin Krause, ArrePath President and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (3)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite